[Table_Reportdate] 2025年04月01日 超配 行 业 简 评 [证券分析师 Table_Authors] 陶圣禹 S0630523100002 tsy@longone.com.cn [table_stockTrend] -29% -12% 4% 21% 38% 54% 71% 24-04 24-07 24-10 25-01 申万行业指数:非银金融(0749) 沪深300 [相关研究 table_product] 1. 从西部收购国融，看中小券商把 握并购浪潮下的区域整合持续落地 ——非银金融行业简评 2. 从国信收购万和，看券商并购趋 势从业务互补迈向国资整合——非 银金融行业简评 行 业 研 究 非 银 金 融 3. 从国君合并海通，看头部整合示 范效应下的航母级券商启航——非 银金融行业简评 [Table_NewTitle 从湘财合并大智慧，看 ] 中小券商与金融 科技跨界整合新路径 ——非银金融行业简评 [table_main] 投资要点： 1）庞大的用户基础带来较大的获客空间：湘财证券截至2024H1末仅有67家证券营业部、 4家业务分公司、4家区域分公司、2家全资子公司，客户触 ...

[Table_Reportdate] 2025年4月1日 [晨会纪要 Table_NewTitle] 20250401 [证券分析师 Table_Authors] 杜永宏 S0630522040001 dyh@longone.com.cn 证券分析师 刘思佳 S0630516080002 liusj@longone.com.cn 证券分析师 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 [Table_Report] ➢ 1. 钒钛股份（000629）：高端产能陆续投放，盈利拐点将至长——公司简评报告 ➢ 2. 关注业绩边际变化————医药生物行业周报（2025/3/24-2025/3/30） ➢ 1.央行：开展8000亿元买断式逆回购操作 ➢ 2.3月公开市场国债买卖情况 ➢ 3.南京全面取消商品房限售 王洋 S0630513040002 wangyang@longone.com.cn [table_main] 重点推荐 财经要闻 晨 会 纪 要 | 1. 重点推荐 | 3 | | --- | --- | | 1.1. 钒钛股份（000629）：高端产 ...

Investment Rating - The industry investment rating is "Overweight" for the non-banking financial sector, indicating a positive outlook compared to the broader market [1][35]. Core Insights - The report highlights a mixed performance in the non-banking financial sector, with a slight decline of 0.1% in the non-banking financial index, while the insurance index showed a positive return of 0.63% [4][8]. - The report emphasizes the expected improvement in brokerage firms' performance driven by investment recovery and the emergence of cross-industry collaborations between brokerages and financial technology [4]. - The introduction of the "20 Articles on Pension Finance" by the financial regulatory authority is expected to guide the development of the pension finance sector, enhancing the financial services available to the elderly population [4][33]. Summary by Sections Market Review - The non-banking financial index decreased by 0.1%, while the brokerage index fell by 0.51% and the insurance index rose by 0.63% [4][8]. - Average daily trading volume in the stock market was 14,950 billion, down 16.5% week-on-week [17]. Brokerage Insights - The securities industry is projected to achieve a net profit of 167.3 billion in 2024, a year-on-year increase of 21.3% [4]. - 28 listed brokerages reported a 15.3% increase in net profit, with a significant 96.6% growth in the fourth quarter, attributed to the recovery in the equity market [4]. - The merger of Xiangcai and Dazhihui is expected to create a new path for brokerage and financial technology collaboration, enhancing user growth and business synergy [4]. Insurance Insights - The "20 Articles on Pension Finance" outlines a five-year plan to establish a pension finance system with Chinese characteristics, focusing on multi-level pension insurance [4][33]. - Listed insurance companies reported significant profit growth in 2024, driven by improvements in the equity market and enhanced product value rates [4]. Investment Recommendations - For brokerages, the report suggests focusing on mergers and acquisitions, high asset turnover, and return on equity (ROE) improvements, recommending investment in large, financially robust brokerages [4]. - In the insurance sector, attention is drawn to large comprehensive insurance companies with competitive advantages, supported by new regulatory policies [4].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [34]. Core Insights - The pharmaceutical and biotechnology sector showed a positive market performance, with an overall increase of 0.98% from March 24 to March 28, 2025, ranking first among 31 industries in the Shenwan index and outperforming the CSI 300 index by 0.97 percentage points [11][30]. - Year-to-date, the sector has risen by 3.53%, ranking 12th among the 31 industries, and has outperformed the CSI 300 index by 4.03 percentage points [16][30]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 27.11 times, which is at a historically low level, with a valuation premium of 126% compared to the CSI 300 index [21][30]. - Notable sub-sectors that performed well include chemical pharmaceuticals and biological products, with increases of 4.04% and 1.17%, respectively [11][30]. Market Performance - The report highlights that 226 stocks (47.68% of the sector) increased in value last week, with the top five performers being Yihe Jiaye (28.58%), Rundu Co. (21.83%), Zhixiang Jintai-U (18.34%), Hehua Co. (16.22%), and Rongchang Bio (15.38%) [28][30]. - Conversely, 235 stocks (49.58% of the sector) experienced declines, with the largest drop being ST Xiangxue at -40.82% [28][30]. Industry News - A significant policy change was announced by six government departments, including the National Health Commission and the Ministry of Finance, which will eliminate outpatient prepayment fees in public medical institutions starting March 31, 2025, and standardize inpatient prepayment management [30][31]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector currently presents significant investment opportunities, particularly in innovative drugs, medical services, chain pharmacies, medical devices, and branded traditional Chinese medicine [5][32]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Nuotai Bio, while stocks to watch include Tebao Bio, Kelun Pharmaceutical, International Medical, Kaili Medical, and Baipusais [5][32].

Investment Strategy and Key Stock Portfolio - The report indicates that the effects of policies are becoming evident, with a gradual shift in the internal and external demand pattern expected to manifest in the second quarter of 2025. Domestic retail sales and fixed asset investment are showing steady improvement, while export growth is declining more significantly than imports, suggesting continued support for GDP from net exports in the first quarter [4][9]. - The report highlights that the performance verification period is underway, with corporate profit growth showing a year-on-year decline in January-February. Revenue growth is also slowing, and profit margins are experiencing seasonal declines. However, profit growth is expected to continue its recovery trend, influenced by the pace and intensity of policy implementation [4][10]. - The report notes an increased risk of stagflation in the U.S., which may affect global market risk appetite. The impending implementation of reciprocal tariffs could have significant impacts on regions outside of China, potentially escalating trade tensions and increasing the likelihood of U.S. stagflation or recession [4][10]. Key Stock Recommendations - The report lists a portfolio of recommended stocks for April 2025, including companies such as Satellite Chemical (002648.SZ), Hengli Petrochemical (600346.SH), and Betta Pharmaceuticals (300558.SZ), among others. Each company is selected based on its industry position and growth potential [3][11]. - Satellite Chemical is highlighted for its integrated industrial chain advantages and its leading position in domestic high-end new materials, with expectations for performance improvement as raw material costs stabilize and market demand recovers [12]. - Hengli Petrochemical is noted for maintaining high growth in the first three quarters of 2024, with strong profitability under high oil prices and a favorable dividend rate, indicating its long-term cash flow stability [12][13]. - Betta Pharmaceuticals is recognized for its innovative drug pipeline and market share growth, particularly in the non-small cell lung cancer sector, with several products gaining rapid market acceptance [12][13]. - The report emphasizes the importance of focusing on sectors with strong certainty in structural market conditions, such as consumer and high-tech industries, while also considering high-dividend sectors in the short term [10]. ETF Recommendations - The report includes recommendations for ETFs, such as Huatai-PB CSI 300 ETF (510300.OF) and Haitong CSI Major Consumer ETF (159928.OF), which are expected to track their respective indices effectively [14]. - The report suggests that these ETFs may provide exposure to sectors that are likely to benefit from the ongoing economic recovery and structural shifts in the market [14].

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [34]. Core Insights - The pharmaceutical and biotechnology sector showed a positive market performance, with an overall increase of 0.98% from March 24 to March 28, 2025, ranking first among 31 industries in the Shenwan index and outperforming the CSI 300 index by 0.97 percentage points [11][30]. - Year-to-date, the sector has risen by 3.53%, ranking 12th among the 31 industries, and has outperformed the CSI 300 index by 4.03 percentage points [16][30]. - The current price-to-earnings (PE) ratio for the sector is 27.11, which is at a historically low level, with a valuation premium of 126% compared to the CSI 300 index [21][30]. - Notable sub-sectors that performed well include chemical pharmaceuticals and biological products, with increases of 4.04% and 1.17%, respectively [11][30]. Market Performance - The pharmaceutical and biotechnology sector's performance is highlighted by the fact that 226 stocks (47.68% of the total) increased in value last week, with the top five performers being Yihe Jiaye (28.58%), Rundu Co., Ltd. (21.83%), Zhixiang Jintai-U (18.34%), Hehua Co., Ltd. (16.22%), and Rongchang Biological (15.38%) [28][30]. - Conversely, 235 stocks (49.58% of the total) experienced declines, with the largest drop being ST Xiangxue at -40.82% [28][30]. Industry News - A significant policy change was announced by six government departments, including the National Health Commission and the Ministry of Finance, which will eliminate outpatient prepayment fees in public medical institutions starting March 31, 2025, and standardize inpatient prepayment management [30][31]. - The policy aims to improve the efficiency of hospital billing and enhance the role of medical insurance funds, which is expected to positively impact the industry [30][31]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector currently presents significant investment opportunities, particularly in innovative drugs, medical services, chain pharmacies, medical devices, and branded traditional Chinese medicine [5][32]. - Recommended stocks include Beida Pharmaceutical, Laobaixing, Lingrui Pharmaceutical, Huaxia Eye Hospital, and Nuotai Biological, while stocks to watch include Tebao Biological, Kelun Pharmaceutical, International Medical, Kaili Medical, and Baipusais [5][32].

[Table_Reportdate] 2025年03月31日 [table_invest] 超配 行 业 周 报 非 银 金 融 [证券分析师 Table_Authors] 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 行 业 研 究 ➢ 行情回顾：上周非银指数下跌0.1%，相较沪深300超跌0.1pp，其中券商与保险指数表现有 所分化，分别为-0.51%和0.63%，保险指数有一定超额收益。市场数据方面，上周市场股 基日均成交额14950亿元，环比上一周降低16.5%；两融余额1.92万亿元，环比上一周小 幅降低0.8%；股票质押市值2.79万亿元，环比上一周降低1.5%。 ➢ 券商：投资改善驱动2024年报业绩改善，券商+金融科技开启跨界组合新路径。1）中证协 披露2024年证券行业数据，全年实现净利润1673亿元，同比增长21.3%，其中经纪、投行、 资管、利息、自营分别同比+17%、-36%、+7%、-6%、+43%，权益市场改善推动经纪、 资管、自营收入高增，而一二级市场逆周期调节下的投行收入大幅压缩也较符合预期；2） 截至上周末，已有28家 ...

[Table_Reportdate] 2025年3月31日 标配 行 业 周 报 [Table_Authors] 证券分析师 方霁 S0630523060001 fangji@longone.com.cn 联系人 董经纬 djwei@longone.com.cn [table_stockTrend] [table_product] 相关研究 1.8月国内手机出货量同比上升 26.7%，联想发布多款AIPC新 品 — — 电 子 行 业 周 报 （20240923-20240929） 1. 国内厂商AI投入持续高增，华为 发布全面搭载鸿蒙的首款阔折叠 Pura X——电子行业周报 （2025/3/17-2025/3/23） 2. 北方华创拟取得芯源微控制权， 关注GTC大会带来的AI产业链机遇 ——电子行业周报（2025/3/10- 2025/3/16） 3. AI Agent产品Manus亮相，AI眼 镜驱动消费电子新一轮增长——电 子行业周报（2025/3/3-2025/3/9） [Table_NewTitle] Semicon展会中国半导体设备产业光彩 四溢，存储龙头释放涨价预期 ——电子行业周报2025 ...

公 司 简 评 买入（维持） 报告原因：业绩点评 ——公司简评报告 [Table_Reportdate] 2025年03月31日 [table_main] 投资要点 ➢ 事件：公司发布2024年年度报告，受下游需求疲软影响、公司主营产品市场价格走低，年 度业绩承压，四季度盈利端环比有所改善。2024年全年公司实现营收132.09亿元，同比- 8.1%；归母净利润2.85亿元，同比-73.0%；毛利率7.6%，同比-6.8pct；净利率2.2%，同 比-5.3pct。2024Q4单季度公司实现营收27.35亿元，同比-15.2%、环比-17.5%；归母净利 润1.02亿元，同比-45.9%、环比+122.0%；毛利率10.3%，同比-4.9pct、环比+4.1pct；净 利率3.6%，同比-2.5pct、环比+2.2pct。 电 力 设 备 与 新 能 源 [数据日期 Table_cominfo] 2025/03/28 收盘价 2.89 总股本(万股) 929,497 流通A股/B股(万股) 929,060/0 资产负债率(%) 16.08% 市净率(倍) 2.10 净资产收益率(加权) 1.50 12个月内最 ...

[Table_Reportdate] 2025年3月31日 标配 行 业 周 报 [Table_Authors] 证券分析师 方霁 S0630523060001 fangji@longone.com.cn 联系人 董经纬 djwei@longone.com.cn [Table_NewTitle] Semicon展会中国半导体设备产业光彩 四溢，存储龙头释放涨价预期 ——电子行业周报2025/3/24-2025/3/30 [table_main] 投资要点： 电 子 证券研究报告 HTTP://WWW.LONGONE.COM.CN 请务必仔细阅读正文后的所有说明和声明 行 业 研 究 [table_stockTrend] [table_product] 相关研究 1.8月国内手机出货量同比上升 26.7%，联想发布多款AIPC新 品 — — 电 子 行 业 周 报 （20240923-20240929） 1. 国内厂商AI投入持续高增，华为 发布全面搭载鸿蒙的首款阔折叠 Pura X——电子行业周报 （2025/3/17-2025/3/23） 2. 北方华创拟取得芯源微控制权， 关注GTC大会带来的AI产业链机 ...